TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors.
Oliveira ÉA, Chauhan J, Silva JRD, Carvalho LADC, Dias D, Carvalho DG, Watanabe LRM, Rebecca VW, Mills G, Lu Y, da Silva ASF, Consolaro MEL, Herlyn M, Possik PA, Goding CR, Maria-Engler SS.
Oliveira ÉA, et al.
Pharmacol Res. 2021 Nov;173:105911. doi: 10.1016/j.phrs.2021.105911. Epub 2021 Sep 22.
Pharmacol Res. 2021.
PMID: 34560251
Free PMC article.